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Summary:  
Rotavirus vaccine in the Kenyan routine immunization program confers considerable 
protection against rotavirus acute gastroenteritis hospitalisation, and protection is sustained 
beyond infancy. Malnutrition appears to diminish vaccine effectiveness, thus improvements 
in nutritional status could maximize vaccine benefits. 
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Abstract 
Background 
Rotavirus remains a leading cause of diarrheal illness and death among children worldwide. 
Data on rotavirus vaccine effectiveness in sub-Saharan Africa are limited. Kenya introduced 
monovalent rotavirus vaccine (RV1) in July 2014. We assessed RV1 effectiveness against 
rotavirus-associated hospitalization in Kenyan children. 
Methods 
Between July-2014 and December-2017, we conducted surveillance for acute gastroenteritis 
(AGE) in three hospitals across Kenya. We analysed data from children age-eligible for ≥1 
RV1 dose, with stool tested for rotavirus and confirmed vaccination history. We compared 
RV1 coverage among those who tested rotavirus-positive (cases) versus rotavirus-negative 
(controls) using multivariable logistic regression; effectiveness was 1-adjusted odds ratio for 
vaccination x100%. 
Results 
Among 677 eligible children, 110 (16%) were rotavirus-positive. Vaccination data were 
available for 91 (83%) cases; 51 (56%) had received 2 RV1 doses and 33 (36%) 0 doses. 
Among 567 controls, 418 (74%) had vaccination data; 308 (74%) had 2 doses and 69 (16%) 0 
doses. Overall 2-dose effectiveness was 64% (95% confidence interval [CI]: 35-80%); for 
children aged <12 months 67% (95%CI: 30-84%) and children aged ≥12 months 72% 
(95%CI: 10-91%). Significant effectiveness was seen in children with normal weight-for-age 
(84% [95%CI: 62-93%]), length/height-for-age (75% [95%CI: 48-88%]) and weight-for-
length/height (84% [95%CI: 64-93%]); however, no protection was found among 
underweight, stunted nor wasted children. 
Conclusions 
RV1 in the routine Kenyan immunization program provides significant protection against 
rotavirus AGE hospitalization. Protection was sustained beyond infancy. Malnutrition 
appears to diminish vaccine effectiveness. Efforts to improve rotavirus vaccine uptake and 
nutritional status are important to maximize vaccine benefit. 
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INTRODUCTION 
Rotavirus remains a leading cause of diarrheal illness and deaths among children worldwide. 
In 2013, rotavirus infection led to ~215,000 deaths among children aged <5 years, with more 
than half occurring in Sub-Saharan Africa [1]. However, rotavirus acute gastroenteritis 
(AGE) is vaccine-preventable. Three live oral rotavirus vaccines are World Health 
Organization (WHO) pre-qualified and available; a monovalent strain (RV1) (Rotarix, 
GlaxoSmithKline) and a pentavalent strain (RV5) (RotaTeq, Merck Vaccines), were pre-
qualified since 2006, while a monovalent vaccine, Rotavac (Bharat Biotech) was pre-
qualified early 2018. In 2009, WHO recommended that rotavirus vaccines be included in all 
national immunization programs, including low-resource settings in Africa and Asia  [2,3].   
Although clinical trials of currently available rotavirus vaccines demonstrated high efficacy 
(generally >85%) against severe rotavirus disease in high-income settings, trials performed in 
resource-poor settings have found substantially lower efficacies (40-60%) [4–6]. Given the 
high burden of severe rotavirus disease in low/middle income countries, as well as lower 
vaccine efficacy, it is important to monitor rotavirus vaccine effectiveness post-introduction 
in such settings. Evidence that rotavirus vaccines prevent rotavirus morbidity and mortality is 
accumulating from observational studies in African countries [7]. However, some studies 
were hampered by limited statistical power, and key questions such as duration of protection 
and effectiveness among malnourished children have not been satisfactorily addressed.  
Kenya introduced RV1 (doses at 6 and 10 weeks) into routine immunization in July 2014. 
Early post-introduction data in Kenya have shown a reduction in the prevalence of rotavirus 
infection among children hospitalized with AGE [8,9]. We evaluated RV1 effectiveness 
against rotavirus AGE hospitalization among Kenyan children.  
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METHODS 
The Rotavirus Immunization Program Evaluation in Kenya (RIPEK) was established as a 
collaboration among institutions with well-established rotavirus surveillance to provide 
country-wide data. This study examined vaccine effectiveness using a case-control design.  
Data from three surveillance sites were included in the analysis (Figure 1). Kilifi County 
Hospital (KCH) is located in the coastal region, serves a rural, semi-rural and urban 
population, with a paediatric bed capacity of 40. Rotavirus surveillance at KCH began in 
2009 and is implemented by KEMRI-Wellcome Trust Research Programme (KWTRP), a 
research partnership between the Kenya Medical Research Institute (KEMRI), the University 
of Oxford and Wellcome Trust, UK [10,11]. Siaya County Referral Hospital (SCRH) serves a 
rural and semi-rural population with a paediatric bed capacity of 60. Rotavirus surveillance 
began in 2010, and is carried out by KEMRI-Centre for Global Health Research (KEMRI-
CGHR) in collaboration with US Centers for Disease Control and Prevention (CDC) as part 
of a network of WHO rotavirus surveillance sites [12]. Saint Elizabeth Lwak Mission 
Hospital (LMH) is a private facility with 7 paediatric beds serving a rural population in 
Asembo, Siaya County. Rotavirus surveillance at LMH is conducted as part of the 
Population-Based Infectious Disease Surveillance (PBIDS) platform [13]. 
At all sites, hospitalised children aged 0-59 months were assessed by trained clinical staff; 
patients with ≥3 loose stools in 24 hours met the AGE case definition. At SCRH, patients 
with ≥1 episode of unexplained vomiting followed by ≥1 loose stool within 24 hours also met 
AGE criteria. Cases with onset ≥7 days prior to admission were excluded. Epidemiologic 
data and a stool sample were collected from AGE case-patients. At SCRH and LMH, stool 
samples were transported on dry ice to KEMRI-CGHR laboratory located ~60 kilometres 
from the facilities; at KCH samples were immediately transported to KWTRP laboratory 
located adjacent to the hospital. Samples at all sites were stored at -80
°
C before testing.  
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Vaccination data for AGE case-patients enrolled at KCH were primarily obtained through an 
electronic vaccine registry [14], which captures childhood immunization data real-time from 
clinics within the area of a Health and Demographic Surveillance System (HDSS) operated 
by KWTRP [10]; vaccination data are linked to KCH surveillance data using unique HDSS 
identification numbers. The HDSS operated by KEMRI-CGHR and CDC in Siaya County 
[15] served as a source of vaccination data for cases enrolled at SCRH and LMH; 
immunization histories for children <5 years were captured by reviewing child health cards 
during household data collection rounds occurring 2-3 times per year. For non-HDSS 
participants enrolled in surveillance at KCH or SCRH, immunization data were captured at 
the time of enrolment; at LMH, surveillance was restricted to HDSS participants. For HDSS 
members enrolled in rotavirus surveillance at SCRH or LMH with missing or uncertain 
vaccination history, household visits were conducted in an attempt to obtain accurate data. 
Stool samples from KCH and SCRH were tested at KWTRP and KEMRI-CGHR 
laboratories, respectively, using the qualitative enzyme immunoassay (EIA) ProsPecT
TM
 
(Oxoid Ltd) for detection of rotavirus Group A VP6 antigen.  For LMH, samples were tested 
at KEMRI-CGHR laboratory using either ProSpecT
TM
 Kit (Oxoid Ltd) or Rotaclone
TM
 Kit 
(Meridian Bioscience) for detection of VP6 antigen [16]. Rotavirus-positive stool samples 
from KCH and SCRH underwent genotyping. KCH samples underwent P and G gene 
amplification followed by Sanger sequencing and genotype determination of assembled 
sequences through the online automated tool RotaC on VIPR[17] at the KWTRP laboratory. 
Samples from SCRH were sent to the Regional WHO Rotavirus Reference Laboratory, 
Medical Research Council-Diarrhoeal Pathogens Research Unit, South Africa for genotyping 
[18]. Samples from LMH were not genotyped. 
We used a test-negative case-control study design to evaluate RV1 effectiveness [19,20], 
utilizing surveillance data collected from July 2014 through December 2017. To demonstrate 
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a vaccine effectiveness of ≥50% (assuming 80% power at the 5% significance level, vaccine 
coverage of 70% and a case to control ratio of 1:2), 105 rotavirus test-positive patients and 
210 rotavirus test-negative controls would have been required. Eligibility criteria included: 
hospitalized with AGE and enrolled in the surveillance platform of a participating site; age-
eligible to have received ≥1 RV1 dose prior to illness, with a 14-day window to allow for 
immunity development (i.e. at least 8 weeks of age at enrolment and born at least 6 weeks 
before vaccine introduction); stool specimen collected and tested for rotavirus; and available 
vaccination history.  
Cases were defined as participants with rotavirus-positive stool, while controls had a 
rotavirus-negative stool. The exposure of interest was RV1 vaccination status (two versus 
zero doses, at least one versus zero doses, and exactly one versus zero doses). A dose was 
considered valid if administered >14 days before date of admission. Vaccination status was 
ascertained using registry/card-confirmed data. However, case-patients without health card 
whose parents reported no prior receipt of any vaccines were considered to have received 
zero RV1 doses. Children without vaccination data or missing date of administration were 
excluded.  
Population-level RV1 coverage was calculated using vaccine registry data in Kilifi and card-
confirmed vaccination data in the HDSS database in Siaya. To calculate annual coverage, we 
assessed each child’s age and vaccination status as of December 31 for that year; coverage 
was defined as the number of children with two RV1 doses divided by the total number of 
children in each age stratum.  
Characteristics of cases and controls were compared using chi-squared test or Mann-
Whitney-U test. We calculated odds ratios for vaccination among cases versus controls using 
unconditional logistic regression, and vaccine effectiveness as 1-odds ratio of vaccination 
x100%. We a priori adjusted for date of admission, age in weeks and site as potential 
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confounders. We assessed for additional potential confounders by including variables in the 
date/age/site-adjusted model; any variable that changed the adjusted odds ratio (aOR) by 
>10% would be included in the final model. Further analyses included examining (a) duration 
of protection by measuring effectiveness stratified by age (<12 months and ≥12 months) (b) 
protection against disease of varying severity using a 20-point clinical Vesikari score, 
classified as less severe (>11) and severe (≥11) [21]; (c) effectiveness among children with 
and without moderate or severe malnutrition. Stunting (low height-for-age) was used as an 
indicator of chronic malnutrition, wasting (low weight-for-height) an indicator of acute 
malnutrition, and underweight (low weight-for-age) a composite of acute and chronic 
malnutrition. All were classified as normal (z-score ≥-2.0), moderate (z-score <-2.0 and ≥-
3.0) or severe (z-score <-3.0) using WHO growth standards [22,23]. All models assessing the 
effectiveness of two versus 0 doses were restricted to data from cases and controls who were 
age-eligible for two doses (≥12 weeks of age, since second dose given at age 10 weeks, plus 
14-day window for immunity development). Malaria was classified based on the presence or 
absence of parasites on blood smear. Analyses were carried out using Stata version 13.1 
(StataCorp).  
The RIPEK protocol was reviewed and approved by KEMRI’s Scientific and Ethical Review 
Unit (SSC #3049) and the Centers for Disease Control and Prevention (Protocol #6968). 
Parents/guardians of participants provided written informed consent for enrolment at each 
participating platform. 
 
RESULTS 
From July 2014 to December 2017, 677 children hospitalized with AGE who were age-
eligible for vaccination with stool collected and tested were identified from the 3 
participating sites. Of these, 110 (16%) were rotavirus-positive cases and 567 (84%) were 
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rotavirus-negative controls (Figure 2). Overall, 509 (75%) had card-confirmed vaccination 
information (or parental report of non-vaccination), including 91 (83%) cases and 418 (74%) 
controls. Among 91 rotavirus-positive cases, 33 (36%) were unvaccinated, 7 (8%) had one 
dose, and 51 (56%) were fully vaccinated. Among 418 rotavirus-negative controls, 69 (16%) 
were unvaccinated, 41 (10%) had one dose, and 308 (74%) were fully vaccinated. There were 
no significant differences between cases and controls in terms of sex, age, site, severity, or 
nutritional status (Table 1). Cases were less frequently fully vaccinated (56%) than controls 
(74%).  
RV1 coverage (2 doses) increased steadily after introduction in all sites, reaching a high in 
2017 of 48% in Siaya, 52% in Lwak and 56% in Kilifi among children aged 6 weeks to 59 
months. Among children aged 12-23 months, coverage was 84-92% in 2017. Among children 
aged 6 weeks to <12 months, coverage initially increased but declined in 2017 across all sites 
(Figure 3). 
Among cases, 69/91 (75%) had genotype information. The most common G-type was G1 
(62%) followed by G2 (28%); the most common P-type was P[8] (67%) followed by P[4] 
(26%) (Table 2). The most frequent combined genotypes were G1P[8] (61%), and G2P[4] 
(26%).  
Effectiveness of two RV1 doses versus zero doses against rotavirus AGE hospitalization was 
64% (95% confidence interval [CI] 35 to 80%), and for exactly one dose 54% (95%CI -20 to 
83%) (Table 3). There was no significant difference in the 2-dose effectiveness among 
children aged <12 months (67%, 95%CI 30 to 84%) and those ≥12 months (72%, 95%CI 10 
to 91%). Effectiveness did not vary significantly by disease severity; for severe cases it was 
67% (95%CI 30 to 84%) and for less severe cases it was 61% (95%CI -10 to 86%).  
The effectiveness of two RV1 doses among children with normal weight-for-age was 84% 
(95%CI 62 to 93%), while for moderately or severely underweight children it was 10% 
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(95%CI -134 to 66%). RV1 effectiveness among those who had normal length/height-for-age 
was 75% (95%CI 48 to 88%) while no significant protection was observed among those who 
were moderately or severely stunted (28%, 95%CI -118 to 76%). Effectiveness among 
children with normal weight-for-length/height was 84% (95%CI 64 to 93%), however, for 
moderately or severely wasted children, no significant protection was observed (-9%, 95%CI 
-224 to 63%). The point estimate of effectiveness at the SCRH site (81%, 95%CI 21 to 96%) 
was higher than that observed in KCH (63%, 95%CI 26 to 82%), although confidence 
intervals were overlapping. In LMH 100% of cases were vaccinated so the model did not 
converge. Vaccine effectiveness stratified by genotype showed statistically significant 
protection against the most common genotype, G1P[8] (60%, 95%CI 3% to 83%). 
 
Discussion 
Using data from ongoing rotavirus surveillance at three health facilities located in two 
different regions of Kenya, we demonstrated 64% (95% CI 35 to 80%) effectiveness of two 
doses of RV1 against hospitalization with rotavirus AGE among young children. We found 
similar estimates of protection among children aged <12 months and ≥12 months.  Despite 
finding robust evidence of effectiveness of the vaccine among well-nourished children, we 
observed no significant protection for children who were stunted, wasted or underweight. The 
lack of effectiveness among malnourished children may help explain the lower efficacy and 
effectiveness of rotavirus vaccines described in low-middle income countries compared to 
that of high-income settings [5].  
The effectiveness against rotavirus hospitalisation in this study is similar to that reported 
from other African countries using RV1, with estimates ranging from 54% to 64% [24–28]. 
This level of protection is also similar to the range of effectiveness found in African countries 
using RV5: 35% [29] and 80% [30], although fewer data are available on RV5 in routine 
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immunization programs in Africa. RV1 effectiveness estimates from other African sites have 
yielded point estimates similar to our results, but without statistically significant confidence 
intervals [31,32]. The statistical power of vaccine effectiveness studies can be affected by 
small numbers and high vaccine coverage [33]. For one of our sites, LMH, the site-specific 
model for vaccine effectiveness did not converge since 100% of cases were vaccinated. Stool 
sample collection from potential cases at LMH was suboptimal, particularly in the early 
phase of this study; cases may have been missed during the immediate post-introduction 
period, when vaccine coverage was still relatively low (Supplementary Table 1). The 
discrepancy in effectiveness estimates between sites within this study highlights some of the 
methodologic challenges of observational vaccine effectiveness studies. Nonetheless, the 
results using data from all three sites provide evidence of robust protection against rotavirus 
hospitalizations in Kenya.    
We found significant RV1 effectiveness with similar point estimates among children aged 
<12 months and those ≥12 months, providing evidence of protection that persists into the 
second year of life. The greatest burden of rotavirus infection is experienced in the first year 
of life, particularly in African settings [34]. Therefore, protection from rotavirus vaccines 
during the first year of life is critical. However, if protection from vaccine declines over time, 
the burden of rotavirus disease could shift to an older age group. Rotavirus vaccine clinical 
trials conducted in Africa raised concerns that protection might wane in the second year of 
life [4,35]. Some post-introduction observational studies in African sites have reported a 
lower effectiveness during the second year of life [28,32,36], while others have found 
estimates of protection to be similar among children aged <12 months and ≥12 months 
[24,27]; however, several of these studies had limited power to assess age-stratified 
effectiveness. Continued monitoring of rotavirus disease burden will be important to assess 
for waning immunity.      
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz664/5536640 by guest on 05 Septem
ber 2019
 12 
 
Stratifying by nutritional status, we found that among well-nourished children, the vaccine 
provided significant protection against rotavirus AGE hospitalisation; however, among 
underweight, wasted and stunted children, there was no significant effectiveness. Studies in 
Botswana [24] and Malawi [36] have similarly found protection of rotavirus vaccine among 
well-nourished children (point estimates of 75% and 78% respectively), but no protection in 
undernourished children. However, in Malawi it was noted that the effectiveness estimates 
among well-nourished and stunted children were not statistically significantly different, and 
in in Botswana (as in our study), there was overlap between the confidence intervals for 
vaccine effectiveness among children with and without malnutrition. Small sample sizes may 
have limited our ability to fully characterize RV1 protection among malnourished children. 
Nonetheless, while several factors may be contributing to the lower levels of protection from 
rotavirus vaccine observed in low-income settings [37], the results of our study and others 
point to a potential role of nutritional status [38]. Therefore, to optimize efforts to reduce 
rotavirus- and diarrhea-related morbidity and mortality in Africa, efforts should be made to 
improve nutrition as well as rotavirus vaccine coverage.    
The RV1 is derived from a monovalent G1P[8] strain and has been shown to protect against 
partially and fully heterotypic genotypes in addition to G1P[8] infections [39,40]. However, 
genotype-specific rotavirus vaccine effectiveness data from post-introduction observational 
studies in Africa are limited. In Malawi, the effectiveness of RV1 was highest for G1P[8] 
genotypes, and lowest against fully heterotypic strains (although 95% confidence intervals 
overlapped). Yet in Botswana, the RV1 was found to be significantly protective against 
G2P[4], which was the predominant genotype. Among genotyped strains in this study, 
G1P[8] was most common (61%), followed by G2P[4] (26%). We observed statistically 
significant protection against G1P[8], albeit with wide confidence intervals (60%, 95% CI 3 
to 83) The point estimate of protection against G2P[4] (31%) was lower than that of G1P[8]; 
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however genotype-specific effectiveness analyses in our study had limited statistical power. 
Given the potential for RV1 to provide lower levels of protection against non-G1P[8] strains, 
it is important to monitoring circulating rotavirus strains post-vaccine introduction.  
A limitation of our study was the exclusion of 17% of cases and 26% of controls due to lack 
of card-confirmed vaccination data; excluding children with missing vaccination data can 
lead to selection bias. However, test-negative designs minimize the potential for selectively 
collecting vaccination histories based on rotavirus positivity, since vaccination history is 
gathered before investigators are aware whether an enrolled child will be a case or a control 
[33]. Our study included only three sites, two of which are located in the same region; 
therefore, the findings may not be generalizable to all regions of Kenya. A prolonged period 
of healthcare worker strikes in 2017 negatively affected enrolment in the surveillance 
platforms (as well as vaccine coverage). Genotype data were only available for a subset of 
cases, which limited our ability to examine strain-specific vaccine effectiveness.  
This study contributes to the growing body of evidence showing that RV1, when used in 
routine infant immunization programs in African countries, can effectively prevent severe 
rotavirus morbidity (hospitalizations) among young children. Although the vaccine 
effectiveness observed is somewhat lower than that seen in high-income settings, it is 
consistent with data from other African settings. We did not see evidence of waning 
protection among children aged ≥12 months. However, our data do suggest that malnutrition 
may diminish RV1 effectiveness. In areas with a high burden of childhood diarrheal illness 
and death, a rotavirus vaccine with 60% effectiveness can prevent much illness and save 
many lives. Efforts to strengthen rotavirus vaccine uptake and improve nutritional status are 
important to maximize vaccine benefit. 
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Tables 
Table 1. Characteristics of rotavirus-positive cases and rotavirus-negative controls among 
children admitted with diarrhea at three hospitals in Kenya, July 2014 to December 2017 
Variable 
Cases (N=91) Controls (N=418) P value 
n (%) n (%)   
Male sex 
 
41 (45) 203 (49) 0.544 
     Median age in months (Range) 9.7 (1.4-29.5) 9.8 (1.4-32.0) 0.667 
Study site  
   
 
Kilifi 61 (67) 277 (66) 
 
 
Lwak 12 (13) 62 (15) 0.916 
 
Siaya 18 (20) 79 (19) 
 Months/season of enrolment      
   
 
Jan-Mar 19 (21) 103 (25) 
 
 
Apr-Jun 25 (27) 140 (33) <0.001 
 
Jul-Sep 39 (43) 93 (22) 
 
 
Oct-Dec 8 (9) 82 (19) 
 Disease severity (Vesikari score)  
   
 
Less severe (<11) 57 (63) 279 (67) 0.453 
 
Severe (≥11) 34 (37) 139 (33) 
 Weight-for-age*  
   
 
Normal (z≥-2) 57 (63) 233 (57) 
 
 
Moderate underweight (z<-2) 15 (16) 70 (17) 0.487 
 
Severe underweight (z<-3) 18 (20) 104 (25) 
 Height-for-age* 
   
 
Normal (z≥-2) 66 (73) 281 (67) 
 
 
 Moderate stunting  (z<-2) 12 (13) 66 (16) 0.419 
 
 Severe stunting (z<-3) 11 (12) 71 (17) 
 Weight-for-height* 
   
 
Normal (z≥-2) 63 (70) 245 (58) 
 
 
Moderate wasting (z<-2) 12 (13) 69 (17) 0.189 
 
Severe wasting (z<-3) 15 (16) 96 (23) 
 
     Positive malaria blood smear* 10 (11) 69 (17) 0.212 
RV1 dose 
   
 
0 doses 33 (36) 69 (15) 
 
 
1 dose 7 (8) 41 (10) <0.001 
  2 doses 51 (56) 308 (74)   
*Missing values excluded from denominator 
Nutritional status measures of Weight-for-age, Height-for-age and Weight-for-height were classified as normal (Z-score ≥-
2), moderate (-3≥Z-score >-2) or severe (z<-3). 
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Table 2. Distribution of genotypes among selected cases from in-patient children enrolled at 3 
hospitals in Kenya between July 2014 and December 2017 
G-type 
P-type 
Total 
P[4] P[6] P[8] P[NT] 
G1 0 0 42 (61%) 1 (1%) 43 (62%) 
G12 0 0 1 (1%) 0 1 (1%) 
G2 18 (26%) 0 1 (1%) 0 19 (28%) 
G3 0 3 (4%) 0 0 3 (4%) 
G3/G9 0 1 (1%) 1 (1%) 0 2 (3%) 
GNT 0 0 1 (1%) 0 1 (1%) 
Total 18 (26%) 4 (6%) 46 (67%) 1 (1%) 69 
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Table 3. Vaccine effectiveness estimates1 by different characteristics for children at 3 hospitals in Kenya between July 2014 and December 2017 
 
1
 Estimates in bold indicate a vaccine effectiveness estimate with a 95% confidence interval with a lower bound >0%. 
2
 Adjusted for date of enrolment, age in weeks and study site. 
3
 Model for effectiveness of 2 vs 0 doses. Excludes 7 cases and 41 controls who received exactly 1 dose. Also excludes 1 case and 12 controls aged <12 wks (therefore not age-eligible for 2 doses). 
4
 Model for effectiveness of 1 dose versus 0 doses. Excludes 51 cases and 308 controls who received 2 doses.
  
 % Vaccinated Crude OR 
(95% CI) 
Crude VE 
(95% CI) 
Adjusted
2
 OR 
(95% CI) 
Adjusted
2
 VE 
(95% CI) Cases (n=91) Controls (n=418) 
Among all age-eligible       
     2 doses
3
 51/83 (61%) 308/365 (84%) 0.29 (0.17-0.50) 71% (50% to 83%) 0.36 (0.20-0.65) 64% (35% to 80%) 
     1 dose
4
 7/40 (18%) 41/110 (37%) 0.36 (0.14-0.88) 59% (12% to 86%) 0.46 (0.17-1.20) 54% (-20 to 83%) 
     ≥1 doses  58/91 (64%) 349/418 (83%) 0.35 (0.21-0.57) 65% (43% to 79%) 0.42 (0.24-0.73) 58% (32 to 78%) 
Age
3
       
     <12 months 33/55 (60%) 184/218 (84%) 0.28 (0.14-0.53) 72% (47% to 86%) 0.33 (0.16-0.70) 67% (30 to 84%) 
     ≥12 months 18/28 (64%) 124/147 (84%) 0.33 (0.14-0.81) 67% (19% to 86%) 0.28 (0.09-0.90) 72% (10 to 91%) 
Study site
3
       
     Kilifi  33/58 (57%) 192/237 (81%) 0.31 (0.18-0.57) 69% (43% to 82%) 0.37 (0.18-0.74) 63% (26 to 82%) 
     Siaya 7/14 (50%) 58/67 (79%) 0.16 (0.04-0.55) 84% (45% to 96%) 0.19 (0.04-0.79) 81% (21 to 96%) 
     Lwak 11/11 (100) 58/61 (95) - - - - 
Disease severity
3
       
     Less severe  34/53 (64%) 206/240 (86%) 0.30 (0.15-0.58) 70% (42% to 85%) 0.33 (0.16-0.70) 67% (30 to 84%) 
     Severe 17/30 (57%) 102/125 (82%) 0.29 (0.13-0.69) 71% (31% to 87%) 0.39 (0.14-1.10) 61% (-10 to 86%) 
Weight for age
3
       
     Normal 28/51 (55%) 184/210 (87%) 0.17 (0.09-0.34) 83% (66% to 91%) 0.16 (0.07-0.38) 84% (62% to 93%) 
     Moderate underweight 8/14 (57%) 55/62 (89%) 0.17 (0.05-0.63) 83% (37% to 95%) 0.33 (0.08-1.46) 67% (-46% to 92%) 
     Severely  underweight 14/17 (82%) 67/90 (74%) 1.60 (0.42-6.08) -60% (-508% to 58%) 1.95 (0.46-8.23) -95% (-723% to 54%) 
     Moderate/Severe underweight 22/31 (70%) 122/152 (80%) 0.64 (0.27-1.52) 36% (-52% to 73%) 0.90 (0.34-2.34) 10% (-134% to 66%) 
Height for age
3
       
     Normal 33/58 (57%) 210/247 (85%) 0.23 (0.12-0.44) 77% (56% to 88%) 0.25 (0.12-0.52) 75% (48% to 88%) 
     Moderate stunting 11/12 (92%) 46/56 (82%) 2.39 (0.27-20.70) -139% (-1970% to 73%) 3.97 (0.40-39.23) -297 (-3823% to 60%) 
     Severe  stunting 6/11 (55%) 52/62 (84%) 0.23 (0.06-0.90) 77% (10% to 94%) 0.31 (0.07-1.50) 69% (-50% to 93%) 
     Moderate/Severe stunting 17/23 (74%) 98/118 (83%) 0.52 (0.19-1.42) 48% (-42% to 81%) 0.72 (0.24-2.18) 28% (-118% to 76%) 
Weight for height
3
       
     Normal 31/57 (54%) 192/218 (88%) 0.16 (0.08-0.31) 84% (69% to 92%) 0.16 (0.07-0.36) 84% (64% to 93%) 
     Moderate wasting 6/11 (55%) 53/61 (87%) 0.18 (0.04-0.73) 82% (27% to 96%) 0.23 (0.04-1.22) 77% (-22% to 96%) 
     Severe wasting 13/14 (93%) 59/81 (73%) 4.84 (0.60-39.27) -384% (-3827% to 40%) 5.59 (0.62-50.11) -459% (-4911% to 38%) 
     Moderate/Severe wasting 19/25 (76%) 112/142 (79%) 0.89 (0.33-2.41) 11% (-141% to 67%) 1.09 (0.37-3.24) -9% (-224% to 63%) 
Genotypes
3,5
       
     G1P[8] 13/32 (41%) 308/365 (84%) 0.13 (0.06-0.27) 87% (73% to 94%) 0.40 (0.17-0.97) 60% (3% to 83%) 
     G2P[4] 15/18 (83) 308/365 (82%) 0.93 (0.26-3.30) 7% (-230% to 74%) 0.71 (0.18-2.84) 29% (-184% to 82%) 
5
 Models restricted to cases with listed genotypes 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz664/5536640 by guest on 05 Septem
ber 2019
 22 
 
Figure Legends 
Figure 1: Map showing the Rotavirus Immunization Program Evaluation in Kenya (RIPEK) 
surveillance sites. 
Figure 2: Flow chart for distribution of rotavirus-positive cases and rotavirus-negative 
controls by vaccination status, among children admitted with diarrhea at three hospitals in 
Kenya, July 2014 to December 2017 
Figure 3: Rotavirus vaccine coverage at different sites by age groups in the populations of 2 
HDSS sites between 2014 and 2017 
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